These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 4472237)

  • 1. Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease.
    Sweet RD; McDowell FH
    Neurology; 1974 Oct; 24(10):953-6. PubMed ID: 4472237
    [No Abstract]   [Full Text] [Related]  

  • 2. Amine precursors in neurologic disorders and the psychoses.
    Klawans H
    Res Publ Assoc Res Nerv Ment Dis; 1975; 54():259-76. PubMed ID: 130667
    [No Abstract]   [Full Text] [Related]  

  • 3. Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.
    Campanella G; Algeri S; Cerletti C; Dolfini E; Jori A; Rinaldi F
    Eur J Clin Pharmacol; 1977 Apr; 11(4):255-61. PubMed ID: 862646
    [No Abstract]   [Full Text] [Related]  

  • 4. [Drug-induced dyskinesia during the treatment of Parkinson disease--biochemical studies].
    Friedman A
    Neurol Neurochir Pol; 1985; 19(5):401-3. PubMed ID: 2421191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients.
    Shoulson I; Glaubiger GA; Chase TN
    Neurology; 1975 Dec; 25(12):1144-8. PubMed ID: 812004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The "on-off" response to chronic L-DOPA treatment of Parkinsonism.
    Sweet RD; McDowell FH
    Adv Neurol; 1974; 5():331-8. PubMed ID: 4440581
    [No Abstract]   [Full Text] [Related]  

  • 7. Parkinson's disease, cerebral arteriosclerosis, and senile dementia. Clinical features and response to levodopa.
    Parkes JD; Marsden CD; Rees JE; Curzon G; Kantamaneni BD; Knill-Jones R; Akbar A; Das S; Kataria M
    Q J Med; 1974 Jan; 43(169):49-61. PubMed ID: 4822972
    [No Abstract]   [Full Text] [Related]  

  • 8. Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy.
    Korf J; van Praag HM; Schut D; Nienhuis RJ; Lakke JP
    Eur Neurol; 1974; 12(5-6):340-50. PubMed ID: 4448192
    [No Abstract]   [Full Text] [Related]  

  • 9. CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders.
    Davidson DL; Yates CM; Mawdsley C; Pullar IA; Wilson H
    J Neurol Neurosurg Psychiatry; 1977 Dec; 40(12):1136-41. PubMed ID: 591981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short- and long-term approaches to the "on-off" phenomenon.
    Papavasiliou PS; Cotzias GC; Mena I
    Adv Neurol; 1974; 5():379-86. PubMed ID: 4440585
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pathomechanism of dyskinesia associated with treatment of Parkinson disease with levodopa].
    Friedman A
    Neurol Neurochir Pol; 1981; 15(4):407-9. PubMed ID: 6173792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid.
    Nishi K; Kondo T; Narabayashi H; Takubo H; Muramoto S; Araki H
    J Neurol Sci; 1989 Aug; 92(1):65-70. PubMed ID: 2475587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy.
    Marsden CD; Parkes JD
    Lancet; 1976 Feb; 1(7954):292-6. PubMed ID: 55599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of clinical response and plasma dopa levels in Parkinson's disease.
    Tolosa ES; Martin WE; Cohen HP; Jacobson RL
    Neurology; 1975 Feb; 25(2):177-83. PubMed ID: 1167646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous dopaminergic stimulation for Parkinson's disease: facts and fancy.
    Obeso JA; Grandas F; Vaamonde J; Luquin MR; Martinez-Lage JM
    Funct Neurol; 1988; 3(4):413-27. PubMed ID: 3072277
    [No Abstract]   [Full Text] [Related]  

  • 16. [Parkinson's disease: neuro-anatomical, biochemical and pharmicotherapeutic aspects].
    Korf J; van Praagen HM; Lakke JP
    Ned Tijdschr Geneeskd; 1975 Sep; 119(36):1373-8. PubMed ID: 241026
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasma DOPA levels and growth hormone response to levodopa in parkinsomism.
    Galea-Debono A; Jenner P; Marsden CD; Parkes JD; Tarsy D; Walters J
    J Neurol Neurosurg Psychiatry; 1977 Feb; 40(2):162-7. PubMed ID: 864480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma levodopa and the "on-off" effect.
    Caine DB; Claveria LE; Allen JG
    Adv Neurol; 1974; 5():341-4. PubMed ID: 4440583
    [No Abstract]   [Full Text] [Related]  

  • 19. Ventricular fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disorders.
    Tabaddor K; Wolfson LI; Sharpless NS
    Neurology; 1978 Dec; 28(12):1249-53. PubMed ID: 569783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
    Rinne UK; Sonninen V; Marttila R
    Adv Neurol; 1975; 9():383-92. PubMed ID: 1096575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.